Tesamorelin: The Peptide That Targets Visceral Fat
LEGAL & MEDICAL DISCLAIMER: The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any peptide therapy or making changes to an existing treatment plan. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed.
Key Takeaways
- Tesamorelin prompts the body to release growth hormone rather than replacing growth hormone directly. It’s a synthetic version of growth hormone-releasing hormone, or GHRH, a natural signal that acts on the pituitary gland.
- Its FDA-approved role is specific. Tesamorelin is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It’s not FDA approved as a general weight loss or body composition treatment.
- The strongest benefits and results relate to visceral fat, not all fat. Clinical trials in people living with HIV found reductions in visceral fat and liver fat, with little to no meaningful reduction in the fat just under the skin.
- Side effects and monitoring matter. Reported effects include joint pain, muscle pain, swelling, nausea, injection-site reactions, and increases in blood glucose or HbA1c. Tesamorelin can also raise insulin-like growth factor 1, or IGF-1, so provider oversight and monitoring are important.
What is Tesamorelin and What Does It Do?
Not all body fat is created equal. The fat that wraps around your internal organs (visceral fat) acts almost like a rogue gland, releasing inflammatory signals and disrupting insulin sensitivity. For decades, researchers looked for a way to selectively target this dangerous fat without stripping away healthy fat elsewhere. The answer came not from a traditional fat-burner, but from a synthetic peptide designed to communicate directly with the pituitary gland.
Tesamorelin has been called the visceral fat peptide. It’s a synthetic analogue of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to your pituitary gland to trigger growth hormone release. The FDA-approved tesamorelin in November 2010 under the brand name Egrifta. It’s the only drug ever approved specifically for HIV-associated lipodystrophy, a condition where long-term antiretroviral therapy causes excess fat to build up in the abdomen.1
Fast Facts
| FULL NAME | Tesamorelin (trans-3-hexenoyl GHRH analogue) |
| CLASS | Growth hormone-releasing hormone (GHRH) analogue; growth hormone secretagogue |
| PRIMARY ACTION | Stimulates pulsatile growth hormone release from the pituitary to reduce visceral adipose tissue (belly fat) |
| ADMINISTRATION | Once-daily subcutaneous injection (FDA-approved dosing) |
| HALF-LIFE | About 26 to 38 minutes in plasma following subcutaneous administration1 |
| RESEARCH | Studied for its potential to reduce belly fat in patients with HIV |
| REGULATORY STATUS | FDA-approved for HIV-associated lipodystrophy; use in other populations remains investigational as of 2026 |
How Does Tesarmorelin Work for Belly Fat?
To understand tesamorelin, it helps to understand the problem it was designed to solve. Native GHRH, the hormone your hypothalamus naturally produces to trigger GH release, has a half-life of just seconds in the bloodstream. An enzyme called dipeptidyl peptidase IV (DPP-IV) destroys this hormone almost immediately, which means it never reaches the pituitary in useful amounts when given as a drug.
The Structural Change That Makes It Work: Tesamorelin is built on the full 44-amino acid sequence of native GHRH, with one key addition: a trans-3-hexenoyl group attached to the N-terminal end of the molecule. This change blocks DPP-IV from breaking down the peptide, greatly extending its stability and allowing it to survive long enough to reach and activate GHRH receptors in the pituitary gland.1
Stimulating Pulsatile GH Release: Once tesamorelin reaches the pituitary gland, it binds to GHRH receptors and prompts the body to release growth hormone the same way it naturally would, in pulses. Rather than adding GH from the outside, tesamorelin works with the body’s own system. That an important difference, because it amplifies an existing pathway instead of replacing it. The body’s built-in feedback controls stay intact, keeping GH levels from climbing too high.¹
Visceral Fat Reduction via IGF-1: The increased GH secretion that tesamorelin triggers leads to higher levels of insulin-like growth factor-1 (IGF-1) in the liver and surrounding tissues. IGF-1 promotes fat breakdown (lipolysis) with a particular focus on belly fat. The targeted effect on deeper fat, and not fat that’s just under the skin, is one of tesamorelin’s most important clinical characteristics.2
What Does the Research Say?
Tesamorelin has been studied in multiple large clinical trials, and the results are consistent: it reliably reduces the dangerous belly fat that builds up in people living with HIV on long-term treatment. Here is what the key studies found. PeptideMatch.io presents this data to help you understand the proven, peer-reviewed clinical outcomes.
| THERAPEUTIC AREA | WHAT RESEARCH SUGGESTS | EVIDENCE LEVEL |
|---|---|---|
| Visceral Fat (HIV Lipodystrophy) | Visceral fat decreased 15.2% with tesamorelin vs. increased 5.0% with placebo; triglycerides fell 50 mg/dL vs. rose 9 mg/dL.1 | Phase 2 Randomized Controlled Trial (RCT) |
| Visceral Fat (Long-Term) | In research, tesamorelin was associated with reductions in fat mass and modest increases in lean mass.2 | Phase 3 RCT |
| Liver Fat | Significant reductions in both visceral fat and liver fat; no significant change in subcutaneous adipose tissue.3 | Phase 3 RCT |
The largest study, a pooled analysis of two Phase 3 trials enrolling 806 HIV patients, found that after 26 weeks, patients taking tesamorelin lost an average of 24 cm2 of deep belly fat (measured by CT scan), while patients on placebo actually gained 2 cm2. By week 52, total visceral fat was down 17.5% from baseline and waist circumference had decreased by 3.4 cm, showing that the drug keeps working over time rather than producing a short-term response that fades.2
Tesamorelin for Visceral Fat and Body Composition
Tesamorelin’s mechanism of stimulating pulsatile GH secretion has broader effects on body composition beyond visceral fat reduction. Growth hormone plays a central role in protein synthesis, lean mass maintenance, and the regulation of fat distribution throughout the body. By restoring GH pulsatility, tesamorelin supports the metabolic environment in which lean tissue is preserved and visceral fat is reduced.
Selective Visceral Fat Loss: Unlike general caloric restriction, tesamorelin reduces visceral fat without significantly affecting fat just under the skin. This matters in HIV lipodystrophy, where patients often already have reduced subcutaneous fat in the limbs and face.2
Lipid Profile Improvements: Triglycerides fell by 37 mg/dL in the Phase 3 trials, and the cholesterol/HDL ratio improved significantly. Both are markers of cardiovascular risk that are elevated in HIV-associated lipodystrophy.2
Liver Fat Reduction: The Stanley 2014 JAMA trial found significant reductions in liver fat, suggesting tesamorelin may benefit patients with liver fat buildup, a common and serious complication of long-term antiretroviral therapy.3
Body Image and Quality of Life: Body image scores, including belly appearance distress and belly profile ratings, improved meaningfully in the tesamorelin group in Phase 3 trials, reflecting the real-world impact of visceral fat reduction on patients’ lives.2
Tesamorelin Side Effects and Safety
Tesamorelin was generally well tolerated across its clinical trial program. The most commonly reported side effects were injection site reactions, joint pain, and peripheral swelling, all consistent with the known actions of growth hormone on fluid balance and connective tissue.2
One important consideration is the rise in IGF-1 levels that comes with tesamorelin use. IGF-1 is a potent growth factor, and chronically elevated levels have been theoretically linked to increased cancer risk, though this association has not been confirmed in clinical trials at therapeutic doses. Periodic monitoring of IGF-1 levels is recommended during treatment. Modest increases in blood glucose and HbA1c have also been observed, requiring close monitoring in patients with diabetes or prediabetes.1
Important Considerations
Injection site reactions, joint pain (arthralgia), muscle pain (myalgia), peripheral swelling, and nausea; generally mild to moderate.2
Modest increases in glucose and HbA1c have been observed; monitor closely in patients with diabetes or prediabetes.1
IGF-1 levels increase significantly during treatment; periodic monitoring is recommended due to theoretical links to cancer risk at elevated levels.
Active malignancy, disruption of the hypothalamic-pituitary axis (e.g., pituitary tumor, prior radiation), and pregnancy.
Visceral fat returns toward baseline after stopping treatment; benefits require ongoing use to be maintained.
Always work with a licensed healthcare provider before considering any peptide therapy or growth hormone-related treatment.
The Bottom Line
Tesamorelin holds a unique place among growth hormone peptides. It’s the only FDA-approved drug specifically designed to reduce visceral fat, the deep belly fat that wraps around your organs and drives metabolic risk. Instead of delivering growth hormone directly, it works by prompting your own pituitary gland to release more GH naturally. The research behind it is solid. Multiple randomized controlled trials, including two large Phase 3 studies, have consistently shown meaningful reductions in visceral fat, improved lipid levels, and better body image in people living with HIV-associated lipodystrophy.²
Scientific References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304.
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389.
©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io.
FAQ
Tesamorelin is a synthetic peptide that acts like growth hormone-releasing hormone, or GHRH. It signals the pituitary gland to release growth hormone in pulses, which can increase insulin-like growth factor 1, or IGF-1. It’s not growth hormone itself. It’s FDA-approved for reducing excess abdominal fat in adults with HIV-related lipodystrophy (an abnormal buildup of fat around organs).
The most established tesamorelin benefits are tied to HIV-associated lipodystrophy. In trials, researchers found reductions in visceral fat, lower triglycerides, and modest changes in lean mass or body image measures. A 2014 clinical trial also found lower liver fat in participants with HIV and abdominal fat accumulation. These findings do not establish tesamorelin as a general treatment for weight loss, bodybuilding, or belly fat in the broader population.
Yes, tesamorelin is FDA approved for a specific use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not FDA approved for general fat loss, muscle building, or anti-aging. An FDA-approved prescribing regimen exists for its approved use. A licensed provider should determine whether tesamorelin is appropriate and how it should be taken and monitored.
Related Posts
Beginning a peptide protocol is a highly personalized patient journey, but even the best science needs a
Orexin is drawing new attention in sleep and energy conversations. What the science shows about its affect on wakefulness,
MK-677 is an oral compound studied for growth hormone support, muscle-building, fat loss, and recovery. We look at the potential
Ready to take the next step?
Find a verified peptide therapy provider or list your practice and connect with patients actively seeking trusted care.